The impact of dietary calcium intake and vitamin D status on the effects of zoledronate
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
We investigated whether baseline dietary calcium intake or vitamin D status modified the effects of zoledronate. Neither variable influenced the effect of zoledronate on bone mineral density, bone turnover, or risk of acute phase reaction, suggesting that co-administration of calcium and vitamin D supplements with zoledronate may not always be necessary.
Calcium and vitamin D supplements are often co-administered with bisphosphonates, but it is unclear whether they are necessary for therapeutic efficacy or minimizing side effects of bisphosphonates. We investigated whether baseline dietary calcium intake or vitamin D status modified the effect of zoledronate on bone mineral density (BMD) or bone turnover at 1 year, or the risk of acute phase reactions (APR).
Data were pooled from two trials of zoledronate in postmenopausal women without vitamin D deficiency in which calcium and vitamin D were not routinely administered. The cohort (zoledronate n = 154, placebo n = 68) was divided into subgroups by baseline dietary calcium intake (<800 vs. ≥800 mg/day) and vitamin D status [25-hydroxyvitamin D (25OHD) <50 vs. ≥50 nmol/L, and <75 nmol/L vs. ≥75 nmol/L] and treatment × subgroup interactions tested.
There were 52, 86, and 36 % of the zoledronate group and 64, 94, and 46 % of the placebo group that had dietary calcium intake ≥800 mg/day, 25OHD ≥50 nmol/L, and 25OHD ≥75 nmol/L, respectively. There were no significant interactions between treatment and either baseline dietary calcium or baseline vitamin D status for lumbar spine BMD, total hip BMD, the bone turnover markers P1NP and β-CTx, or the risk of an APR. There was also no three-way interaction between baseline dietary calcium intake, baseline vitamin D status, and treatment for any of these variables.
Baseline dietary calcium intake and vitamin D status did not alter the effects of zoledronate, suggesting that co-administration of calcium and vitamin D with zoledronate may not be necessary for individuals not at risk of marked vitamin D deficiency.
- Adami S, Giannini S, Bianchi G et al (2009) Vitamin D status and response to treatment in post-menopausal osteoporosis. Osteoporos Int 20:239–244 CrossRef
- Carmel AS, Shieh A, Bang H et al. (2012) The 25(OH)D level needed to maintain a favorable bisphosphonate response is ≥33 ng/ml. Osteoporos Int (in press)
- Antoniucci DM, Vittinghoff E, Palermo L et al (2009) Vitamin D insufficiency does not affect response of bone mineral density to alendronate. Osteoporos Int 20:1259–1266 CrossRef
- Bonnick S, Broy S, Kaiser F et al (2007) Treatment with alendronate plus calcium, alendronate alone, or calcium alone for postmenopausal low bone mineral density. Curr Med Res Opin 23:1341–1349 CrossRef
- McCloskey EV, Beneton M, Charlesworth D et al (2007) Clodronate reduces the incidence of fractures in community-dwelling elderly women unselected for osteoporosis: results of a double-blind, placebo-controlled randomized study. J Bone Miner Res 22:135–141 CrossRef
- Grey A, Bolland MJ, Wattie D et al (2009) The antiresorptive effects of a single dose of zoledronate persist for two years: a randomized, placebo-controlled trial in osteopenic postmenopausal women. J Clin Endocrinol Metab 94:538–544 CrossRef
- Grey A, Bolland M, Wattie D et al (2010) Prolonged antiresorptive activity of zoledronate: a randomized, controlled trial. J Bone Miner Res 25:2251–2255 CrossRef
- Black DM, Delmas PD, Eastell R et al (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809–1822 CrossRef
- Lyles KW, Colon-Emeric CS, Magaziner JS et al (2007) Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357:1799–1809 CrossRef
- Reid IR, Gamble GD, Mesenbrink P et al (2010) Characterization of and risk factors for the acute-phase response after zoledronic acid. J Clin Endocrinol Metab 95:4380–4387 CrossRef
- Bertoldo F, Pancheri S, Zenari S et al (2010) Serum 25-hydroxyvitamin D levels modulate the acute-phase response associated with the first nitrogen-containing bisphosphonate infusion. J Bone Miner Res 25:447–454 CrossRef
- Grey A, Bolland M, Wong S et al (2012) Low-dose zoledronate in osteopenic postmenopausal women: a randomized controlled trial. J Clin Endocrinol Metab 97:286–292 CrossRef
- Angus RM, Sambrook PN, Pocock NA et al (1989) A simple method for assessing calcium intake in Caucasian women. J Am Diet Assoc 89:209–214
- Antoniucci DM, Vittinghoff E, Blackwell T et al (2005) Vitamin D insufficiency does not affect bone mineral density response to raloxifene. J Clin Endocrinol Metab 90:4566–4572 CrossRef
- Dawson-Hughes B, Chen P, Krege JH (2007) Response to teriparatide in patients with baseline 25-hydroxyvitamin D insufficiency or sufficiency. J Clin Endocrinol Metab 92:4630–4636 CrossRef
- Bolland MJ, Bacon CJ, Horne AM et al (2010) Vitamin D insufficiency and health outcomes over 5 y in older women. Am J Clin Nutr 91:82–89 CrossRef
- The impact of dietary calcium intake and vitamin D status on the effects of zoledronate
Volume 24, Issue 1 , pp 349-354
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Acute phase reaction
- Bone mineral density
- Dietary calcium intake
- Vitamin D
- Industry Sectors
- Author Affiliations
- 1. Department of Rheumatology, Auckland City Hospital, Auckland, New Zealand
- 2. Bone and Joint Research Group, Department of Medicine, University of Auckland, Private Bag 92 019, Auckland, 1142, New Zealand